论文部分内容阅读
作者前瞻性随机取样研究浅表膀胱癌经尿道电切(TUR)后膀胱内灌注阿霉素长期与短期后对肿瘤复发、肿瘤升级及对生存率进行比较。146例患者TUR后经组织切片证实肿瘤已切净,随机分三组,短期组76人,术后每周灌注阿霉素50mg一次,共6周,长期组70人,同样灌注6周后,改为每月灌注一次50mg,共2年,术后每3月膀胱镜检,并取6～7处多部位活检,2年后改每半年一次直至5年。若有肿瘤复发,TUR后从新开始6周的灌注,146例患者年龄29～85岁(平均68岁),64％为男性,50％肿瘤侵犯到固有膜,17％为癌
The authors prospective randomized study of superficial bladder cancer transurethral resection (TUR) after intravesical instillation of doxorubicin for long-term and short-term tumor recurrence, tumor progression and survival rates were compared. 146 patients with TUR confirmed by tissue section after the tumor has been cut net, were randomly divided into three groups, short-term group of 76 patients, weekly doxorubicin 50mg once a total of 6 weeks, long-term group of 70 people, the same perfusion 6 weeks later, Change to 50mg once a month for a total of 2 years, postoperative cystoscopy every 3 months, and take 6 to 7 multi-site biopsy, 2 years later changed every six months until 5 years. If there is a tumor recurrence, TUR after reinfusion 6 weeks after the start, 146 patients aged 29 to 85 years (mean 68 years old), 64% were male, 50% of tumors invade the lamina propria, 17% of cancer